Opioid prescribing in general practice: use of a two

Long-term opioid analgesic prescribing in chronic non-cancer pain (CNCP) is a growing worldwide concern. This has implications for optimal healthcare management in general and chronic pain management specifically. This work documents the development of a review tool and its use in the South West of England in a locality that showed opioid prescribing levels higher than surrounding localities. An electronic tool which enabled calculation of total prescribed morphine-equivalent doses was developed to allow general practitioners (GPs) to undertake reviews of CNCP patients. This tool was used to assess strong opioid prescribing over a 3-month period at every GP practice (n？=？41) in the locality. Every prescription for morphine, oxycodone, pethidine and fentanyl during this period was included. Aspects assessed included drug(s) prescribed, dose prescribed, whether tramadol was prescribed concurrently, whether the drugs were potentially being overused and/or whether the patient was in palliative care. Patients prescribed over 120？mg morphine equivalent per day were reviewed in greater depth, as this is an indication for specialist input. In total, 1881 patients received a prescription in the assessment period. Morphine was the most commonly prescribed drug (n？=？847). In all, 363 CNCP patients were prescribed a dose equal to or above 120？mg morphine a day, with a maximum morphine-equivalent dose of 890？mg being prescribed. Over 11% (n？=？211) of patients were concurrently prescribed tramadol. The most frequently cited reason for prescription of high-dose opioids was found to be a musculoskeletal pain of the back, neck, joints or limbs. The care of 85 specific CNCP patients was reviewed and optimised. No published work to date has documented such an in-depth analysis of primary-care opioid analgesic prescribing utilising prescriber data. Assessing total-dose morphine-equivalent prescribing using this method provides valuable insights into the potential need for urgent medication review. The tool developed may be of value to other GP practices following validation